| Primary | Time From First Dose to Urinary Continence | Urinary continence is defined as the first of three consecutive 24-hour days in which a participant uses no pads, or a pad for security which remains completely dry, during the 12-week treatment period. Participants recorded their daily pad usage in an electronic diary. Kaplan-Meier curves were used to estimate the distribution of cumulative incidence of urinary continence over the 12-week study treatment period. Participants who did not experience the event during the 12-week treatment period were considered as censored at the End of Treatment (EOT) visit or Week 12, whichever occurs first. | Full analysis set defined as all randomized participants who took at least one dose of study drug and had at least one efficacy endpoint evaluation. | Posted | | Median | 95% Confidence Interval | days | | 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG000NA(93.0 to NA)Data were not observed during 12-week treatment period due to low incidence of continence events.
- OG001NA(NA to NA)Data were not observed during 12-week treatment period due to low incidence of continence events.
|
|
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| The treatment difference in the primary efficacy variable was tested using a log-rank test stratified by (pooled) center and by Baseline daily pad usage (≤3 and >3) at a 2-sided significance level of 0.05. | Log Rank | Based on a Log-rank test stratified by (pooled) center and Baseline daily pad usage (≤ 3 and > 3). | 0.1745 | | | | | | 2-Sided | | | | | | | | Superiority or Other (legacy) | | |
|
| Secondary | Percentage of Participants Who Gain Continence During 12-week Treatment Period | Urinary continence is defined as three consecutive 24-hour days in which a participant uses no pads or a pad for security which remains completely dry. Participants recorded their daily pad usage in an electronic diary during the 12-week treatment period. End of treatment is the last on-treatment assessment during the treatment period. | Full analysis set; the calculation of percentage of participants uses the full analysis set as the denominator at each time point. | Posted | | Number | | percentage of participants | | Weeks 4, 8, and 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
| |
| Secondary | Average Daily Pad Usage at Baseline | Participants recorded their daily pad usage in an electronic diary during the 12-week treatment period. A 7-day window was used to calculate the average daily pad usage. | Full analysis set with available pad usage data at Baseline. | Posted | | Mean | Standard Deviation | pads | | Baseline (7 days prior to Day 1) | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
| |
| Secondary | Change From Baseline in Average Daily Pad Usage | Participants recorded their daily pad usage in an electronic diary during the 12-week treatment period. A 7-day window was used to calculate the average daily pad usage. End of treatment is the last on-treatment assessment during the treatment period. | Full analysis set with available pad usage data at both Baseline and each time point; "n" indicates the number of participants with available data at each time point. | Posted | | Least Squares Mean | Standard Error | pads | | Baseline and Weeks 4, 8 and 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
| |
| Secondary | American Urology Association Symptom Score (AUASS) at Baseline | Quality of life was measured by the American Urology Association Symptom Score (AUASS). The AUASS includes 7 questions addressing symptoms of frequency, urgency, nocturia (waking during the night to urinate), hesitancy, weak urinary, incomplete emptying, and intermittence. The questionnaire asked participants to consider how these symptoms affected them over the past month on a scale from 0 (not at all) to 5 (almost always). The AUASS is a sum of the 7 symptom scores and ranges from 0 (best) to 35 (worst). | Full analysis set with available AUASS data at Baseline. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
| |
| Secondary | Change From Baseline in American Urology Association Symptom Score (AUASS) | Quality of life was measured by the American Urology Association Symptom Score (AUASS). The AUASS includes 7 questions addressing symptoms of frequency, urgency, nocturia (waking during the night to urinate), hesitancy, weak urinary, incomplete emptying, and intermittence. The questionnaire asked participants to consider how these symptoms affected them over the past month on a scale from 0 (not at all) to 5 (almost always). The AUASS Symptom Score is a sum of the 7 symptom scores and ranges from 0 (best) to 35 (worst). End of treatment is the last on-treatment assessment during the treatment period. | Full analysis set with available AUASS data at both Baseline and each time point; "n" indicates the number of participants with available data at each time point. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline and Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
| |
| Secondary | American Urology Association Quality of Life (QOL) Score at Baseline | The American Urology Association (AUA) includes a single bother question which asked participants how they would feel if they had to live with their urinary condition the way it is now for the rest of their life. The bother question score ranges from 0 (delighted) to 6 (terrible). | Full analysis set with available AUA QOL data at Baseline. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
| |
| Secondary | Change From Baseline in American Urology Association Quality of Life (QOL) Score | The American Urology Association (AUA) includes a single bother question which asked participants how they would feel if they had to live with their urinary condition the way it is now for the rest of their life. The bother question score ranges from 0 (delighted) to 6 (terrible). End of treatment is the last on-treatment assessment during the treatment period. | Full analysis set with available AUA data at both Baseline and each time point; "n" indicates the number of participants with available data at each time point. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline and Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
| |
| Secondary | International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) QOL Score at Baseline | The ICIQ-SF is a validated self-administered questionnaire designed for patients with urinary incontinence. The ICIQ-SF assessed urinary incontinence using 3 scored questions which ask patients about their frequency of urine leakage, how much urine leakage, and perceived impact of leakage on daily lives over the past 4 weeks. The ICIQ-SF is a sum of the 3 scores and ranges from 0 (low bother) to 21 (maximum bother). | Full analysis set with available ICIQ-SF QOL data at Baseline. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
| |
| Secondary | Change From Baseline in International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) QOL Score | The ICIQ-SF is a validated self-administered questionnaire designed for patients with urinary incontinence. The ICIQ-SF assessed urinary incontinence using 3 scored questions which ask patients about their frequency of urine leakage, how much urine leakage, and perceived impact of leakage on daily lives over the past 4 weeks. The ICIQ-SF is a sum of the 3 scores and ranges from 0 (low bother) to 21 (maximum bother). | Full analysis set with available ICIQ-SF data at both Baseline and each time point; "n" indicates the number of participants with available data at each time point. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline and Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
| |
| Secondary | Baseline Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed | Work productivity was measured by the Work Productivity and Activity Impairment Questionnaire (WPAI). WPAI asks participants about the effect of urinary leakage on their ability to perform their work-related functions and carry out daily activities over the past seven days. Percent work time missed is derived from the number of hours of work missed due to urinary leakage as a percentage of total hours that should have been worked. A higher percentage indicates more hours missed. | Full analysis set participants who were employed prior to the study and with available WPAI data at Baseline. | Posted | | Mean | Standard Deviation | percent work time missed | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
| |
| Secondary | Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed | Work productivity was measured by the Work Productivity and Activity Impairment Questionnaire (WPAI). WPAI asks participants about the effect of urinary leakage on their ability to perform their work-related functions and carry out daily activities over the past seven days. Percent work time missed is derived from the number of hours of work missed due to urinary leakage as a percentage of total hours that should have been worked. A higher percentage indicates more hours missed. A negative change from Baseline indicates improvement. | Full analysis set including participants who were employed prior to the study and with available WPAI data at both Baseline and each time point; "n" indicates the number of participants with available data at each time point. | Posted | | Least Squares Mean | Standard Error | Percent work time missed | | Baseline and Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
| |
| Secondary | Baseline Work Productivity and Activity Impairment (WPAI): Percent Impairment While Working | Work productivity was measured by the Work Productivity and Activity Impairment Questionnaire (WPAI). WPAI asks participants about the effect of urinary leakage on their ability to perform their work-related functions and carry out daily activities over the past seven days. Percent impairment while working was derived from the participant's assessment of the degree to which urinary leakage affected their productivity while working. A higher percentage indicates greater impairment and less productivity. | Full analysis set participants who were employed prior to the study and with available WPAI data at Baseline. | Posted | | Mean | Standard Deviation | percent impairment while working | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
| |
| Secondary | Change From Baseline in Work Productivity Assessment Index (WPAI): Percent Impairment While Working | Work productivity was measured by the Work Productivity and Activity Impairment Questionnaire (WPAI). WPAI asks participants about the effect of urinary leakage on their ability to perform their work-related functions and carry out daily activities over the past seven days. Percent impairment while working was derived from the participant's assessment of the degree to which urinary leakage affected their productivity while working. A higher percentage indicates greater impairment and less productivity. A negative change from Baseline indicates improvement. | Full analysis set including participants who were employed prior to the study and with available WPAI data at both Baseline and each time point; "n" indicates the number of participants with available data at each time point. | Posted | | Least Squares Mean | Standard Error | percent impairment while working | | Baseline and Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
| |
| Secondary | Baseline Work Productivity and Activity Impairment (WPAI): Percent Overall Work Impairment | Work productivity was measured by the Work Productivity and Activity Impairment Questionnaire (WPAI). WPAI asks participants about the effect of urinary leakage on their ability to perform their work-related functions and carry out daily activities over the past seven days. Percent overall work impairment takes into account both hours missed due to urinary leakage and the participant's assessment of the degree to which urinary leakage affected their productivity while working. A higher percentage indicates greater impairment and less productivity. | Full analysis set participants who were employed prior to the study and with available WPAI data at Baseline. | Posted | | Mean | Standard Deviation | percent overall work impairment | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
| |
| Secondary | Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Overall Work Impairment | Work productivity was measured by the Work Productivity and Activity Impairment Questionnaire (WPAI). WPAI asks participants about the effect of urinary leakage on their ability to perform their work-related functions and carry out daily activities over the past seven days. Percent overall work impairment takes into account both hours missed due to urinary leakage and the participant's assessment of the degree to which urinary leakage affected their productivity while working. A higher percentage indicates greater impairment and less productivity. A negative change from Baseline indicates improvement. | Full analysis set including participants who were employed prior to the study and with available WPAI data at both Baseline and each time point; "n" indicates the number of participants with available data at each time point. | Posted | | Least Squares Mean | Standard Error | percent overall work impairment | | Baseline and Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
|
| Secondary | Baseline Work Productivity and Activity Impairment (WPAI): Percent Activity Impairment | Work productivity was measured by the Work Productivity and Activity Impairment Questionnaire (WPAI). WPAI asks participants about the effect of urinary leakage on their ability to perform their work-related functions and carry out daily activities over the past seven days. Percent activity impairment is derived from the participant's assessment of the degree to which their urinary leakage affected their regular daily activities. A higher percentage indicates greater impairment and less productivity. | Full analysis set participants with available WPAI data at Baseline. | Posted | | Mean | Standard Deviation | percent activity impairment | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
| |
| Secondary | Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Activity Impairment | Work productivity was measured by the Work Productivity and Activity Impairment Questionnaire (WPAI). WPAI asks participants about the effect of urinary leakage on their ability to perform their work-related functions and carry out daily activities over the past seven days. Percent activity impairment is derived from the participant's assessment of the degree to which their urinary leakage affected their regular daily activities. A higher percentage indicates greater impairment and less productivity. A negative change from Baseline indicates improvement. | Full analysis set with available WPAI data at both Baseline and each time point; "n" indicates the number of participants with available data at each time point. | Posted | | Least Squares Mean | Standard Error | Percent activity impairment | | Baseline and Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
| |
| Secondary | Time From Baseline to First Day of Returning to Work | The time from Baseline to first day of returning to work was estimated using the Kaplan-Meier method. | Full analysis set participants who were employed prior to the study. | Posted | | Median | 95% Confidence Interval | days | | From Baseline to Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received matching placebo tablets once a day for 12 weeks. | | OG001 | Solifenacin Succinate | Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily. |
| |